Related Experiment Video
Updated: Jun 10, 2025
07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
34.5K
Cryoablation for unresectable unicentric Castleman disease.
Yoshito Nishimura1, Thomas Atwell1, Matthew Callstrom1
1Mayo Clinic, Rochester, Minnesota, USA.
American Journal of Hematology
|October 16, 2024
Summary
This study details laboratory findings and treatment timelines, starting from the initial consult on Day 0. Key markers like C-reactive protein (CRP) and immunoglobulin G (IgG) were monitored throughout the patient
Area of Science:
- Clinical laboratory science
- Immunology
- Medical treatment monitoring
Background:
- Establishing a baseline for patient care is crucial.
- Understanding treatment progression requires detailed timelines.
- Monitoring key biomarkers aids in assessing patient response.
Observation:
- Laboratory results were systematically recorded.
- Treatment interventions were administered over a defined period.
- Patient progress was documented from initial consultation.
Findings:
- Changes in C-reactive protein (CRP) levels were observed.
- Immunoglobulin G (IgG) levels were tracked.
- The timeline correlated laboratory findings with treatment events.
Implications:
- Provides a framework for analyzing treatment efficacy.
- Highlights the importance of serial laboratory monitoring.
- Informs clinical decision-making for similar cases.
